Table 4.
Comparative Diagnosis | Biomarkers | Crude | Adjusted | ||
---|---|---|---|---|---|
OR (95% CI) | p-Value | OR * (95% CI) | p-Value | ||
Normal vs. CCA | cfDNA < 0.2175 vs. ≥ 0.2175 ng/µL | 227.86 (26.73–1942.52) | <0.0001 | 227.05 (25.93–1988.27) | <0.0001 |
Normal vs. BBD | cfDNA < 0.0897 vs. ≥ 0.0897 ng/µL | 32.86 (7.65–141.13) | <0.0001 | 101.46 (10.70–961.76) | <0.0001 |
BBD vs. CCA | cfDNA < 0.3388 vs. ≥ 0.3388 ng/µL | 6.29 (2.44–16.26) | <0.0001 | 7.649 (2.72–21.50) | <0.0001 |
BBD vs. CCA | CA19-9 < 39.90 vs. ≥ 39.90 U/mL | 2.30 (0.94–5.62) | 0.068 | 2.18 (0.86–5.46) | 0.099 |
BBD vs. CCA | CEA < 2.53 vs. ≥ 2.53 ng/mL | 0.61 (0.26–1.42) | 0.251 | 0.56 (0.23–1.37) | 0.204 |
* Odds ratio adjusted for age and sex statistical analysis. Abbreviations; OR: odds ratio, CI: confidence interval, CCA: cholangiocarcinoma, BBD: benign biliary disease. A p-value < 0.05 was considered statistically significant.